Mannitol Use During Cadaveric Kidney Transplantation
Status:
Not yet recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
We propose a placebo controlled randomized study on the use of mannitol as an agent to
protect against delayed graft function, during the surgical procedure of kidney
transplantation from a cadaver. Patients undergoing kidney transplantation for the treatment
of end stage kidney disease will be randomized in a ratio of 1:1 to receive either
intravenous mannitol or saline during their procedure, administered prior to renal artery
clamp release and reperfusion of the kidney. Changes in renal function following surgery and
the incidence and duration of delayed graft function (DGF) will be monitored using calculated
glomerular filtration rate (eGFR) and the need for dialysis performed post-operatively, as
part of routine standard of care. Additionally biological samples will be collected and
analyzed for use of a non invasive biomarker for delayed graft function.